Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;14(3):467-482.
doi: 10.3233/JPD-230376.

Parkinson's Disease is Predominantly a Genetic Disease

Affiliations
Review

Parkinson's Disease is Predominantly a Genetic Disease

Shen-Yang Lim et al. J Parkinsons Dis. 2024.

Abstract

The discovery of a pathogenic variant in the alpha-synuclein (SNCA) gene in the Contursi kindred in 1997 indisputably confirmed a genetic cause in a subset of Parkinson's disease (PD) patients. Currently, pathogenic variants in one of the seven established PD genes or the strongest known risk factor gene, GBA1, are identified in ∼15% of PD patients unselected for age at onset and family history. In this Debate article, we highlight multiple avenues of research that suggest an important - and in some cases even predominant - role for genetics in PD aetiology, including familial clustering, high rates of monogenic PD in selected populations, and complete penetrance with certain forms. At first sight, the steep increase in PD prevalence exceeding that of other neurodegenerative diseases may argue against a predominant genetic etiology. Notably, the principal genetic contribution in PD is conferred by pathogenic variants in LRRK2 and GBA1 and, in both cases, characterized by an overall late age of onset and age-related penetrance. In addition, polygenic risk plays a considerable role in PD. However, it is likely that, in the majority of PD patients, a complex interplay of aging, genetic, environmental, and epigenetic factors leads to disease development.

Keywords: GBA1; LRRK2; PRKN; Parkinson’s disease; environment; epigenetic; familial; gene-environment interactions; genetics; monogenic; pandemic; polygenic; progression.

PubMed Disclaimer

Conflict of interest statement

SYL has received consultancy or lecturing honoraria from the GP2 (the GP2 is funded by the Aligning Science Across Parkinson’s (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson’s Research (https://gp2.org)); Lundbeck International Neuroscience Foundation (Neurotorium) Editorial Board; International Parkinson and Movement Disorder Society (MDS); Eisai; Lundbeck; and Medtronic.

CK is a medical advisor to Centogene and Retromer Therapeutics and received Speakers’ honoraria from Bial and Desitin.

Figures

Fig. 1
Fig. 1
Screenshot from the MDSGene website (https://www.mdsgene.org, accessed on 5 November 2023), here depicting, as an example, the updated statistics on PARK-PRKN cases reported worldwide with individual-level data (almost 1,500 cases). The website also provides curated data regarding patients’ clinical characteristics and the pathogenicity classification of genetic variants.
Fig. 2
Fig. 2
Screenshot from the Global Parkinson’s Genetics Program (GP2) website (https://gp2.org, accessed on 5 November 2023), depicting the updated statistics on an ever-growing number of contributing sites and samples.

References

    1. Lim SY, Tan AH, Fox SH, Evans AH, Low SC (2017) Integrating patient concerns into Parkinson’s disease management. Curr Neurol Neurosci Rep 17, 3. - PubMed
    1. Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49, 328–338. - PubMed
    1. Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397, 2284–2303. - PubMed
    1. Wüllner U, Borghammer P, Choe CU, Csoti I, Falkenburger B, Gasser T, Lingor P, Riederer P (2023) The heterogeneity of Parkinson’s disease. J Neural Transm (Vienna) 130, 827–838. - PMC - PubMed
    1. Periñán MT, Brolin K, Bandres-Ciga S, Blauwendraat C, Klein C, Gan-Or Z, Singleton A, Gomez-Garre P, Swanberg M, Mir P, Noyce A (2022) Effect modification between genes and environment and Parkinson’s disease risk. Ann Neurol 92, 715–724. - PMC - PubMed

Publication types

MeSH terms

Substances